Glycosylation Targeting: A Paradigm Shift in Cancer Immunotherapy

Overview

Journal Int J Biol Sci

Specialty Biology

Date 2024 May 10

PMID 38725856

Authors

Xueting Ren

Shuai Lin

Feng Guan

Huafeng Kang

Affiliations

Soon will be listed here.

Abstract

Immunotherapy has shown great potential in cancer treatment. However, even with the intervention of techniques such as immune checkpoint inhibitor therapy, tumors can still achieve immune escape, leading to a low response rate. Abnormal glycosylation is a widely recognized hallmark of cancer. The development of a complex "glyco-code" on the surface of tumor cells can potentially influence the immune system's ability to monitor tumors and can impact the anti-tumor immune response. Therefore, abnormal glycosylation has emerged as a promising target for immunotherapy. Many recent studies have shown that targeted glycosylation can reshape the tumor microenvironment (TME) and promote the immune response, thereby improving the response to immunotherapy. This review summarizes how glycosylation affects anti-tumor immune function in the TME and synthesizes the latest research progress on targeted glycosylation in immunotherapy. It is hoped that by elucidating the basic laws and biological connotations of glycosylation, this review will enable researcher to thoroughly analyze the mechanism of its influence on the immune metabolic regulation network, which will provide a theoretical tool for promoting the clinical application of glycosylation codes.

Citing Articles

Glycoscience in Advancing PD-1/PD-L1-Axis-Targeted Tumor Immunotherapy.

Sun Q, Hong S Int J Mol Sci. 2025; 26(3).

PMID: 39941004 PMC: 11818636. DOI: 10.3390/ijms26031238.

Bisecting GlcNAc modification of vesicular GAS6 regulates CAFs activation and breast cancer metastasis.

Li J, Ren X, Cao L, Min K, Wang M, Lin S Cell Commun Signal. 2025; 23(1):39.

PMID: 39844194 PMC: 11755815. DOI: 10.1186/s12964-025-02052-y.

Directed Mutagenesis for Arginine Substitution of a Recombinant Lectin Disrupts Its Cytotoxic Activity.

Martinez-Alarcon D, Castro-Guillen J, Fitches E, Gatehouse J, Przyborski S, Moreno-Celis U Int J Mol Sci. 2025; 25(24.

PMID: 39769023 PMC: 11676905. DOI: 10.3390/ijms252413258.

Deciphering the cell surface glyco-code: a promising perspective on unveiling the vulnerability of cancer stem cells.

Wei Y, Wei A, Li Y, Yang Y, Si Y, Li Y Cancer Biol Med. 2024; 21(11).

PMID: 39663772 PMC: 11667778. DOI: 10.20892/j.issn.2095-3941.2024.0408.

Tertiary lymphoid structures in anticancer immunity.

Teillaud J, Houel A, Panouillot M, Riffard C, Dieu-Nosjean M Nat Rev Cancer. 2024; 24(9):629-646.

PMID: 39117919 DOI: 10.1038/s41568-024-00728-0.

References

Zhang N, Li M, Xu X, Zhang Y, Liu Y, Zhao M . Loss of core fucosylation enhances the anticancer activity of cytotoxic T lymphocytes by increasing PD-1 degradation. Eur J Immunol. 2020; 50(11):1820-1833. DOI: 10.1002/eji.202048543. View

Garcia-Garcia A, Ceballos-Laita L, Serna S, Artschwager R, Reichardt N, Corzana F . Structural basis for substrate specificity and catalysis of α1,6-fucosyltransferase. Nat Commun. 2020; 11(1):973. PMC: 7033129. DOI: 10.1038/s41467-020-14794-z. View

Huang Y, Zhang H, Li Z, Du T, Chen Y, Wang Y . FUT8-mediated aberrant N-glycosylation of B7H3 suppresses the immune response in triple-negative breast cancer. Nat Commun. 2021; 12(1):2672. PMC: 8113546. DOI: 10.1038/s41467-021-22618-x. View

Fry T, Shah N, Orentas R, Stetler-Stevenson M, Yuan C, Ramakrishna S . CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy. Nat Med. 2017; 24(1):20-28. PMC: 5774642. DOI: 10.1038/nm.4441. View

Wang J, Sun J, Liu L, Flies D, Nie X, Toki M . Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy. Nat Med. 2019; 25(4):656-666. PMC: 7175920. DOI: 10.1038/s41591-019-0374-x. View

Schjoldager K, Narimatsu Y, Joshi H, Clausen H . Global view of human protein glycosylation pathways and functions. Nat Rev Mol Cell Biol. 2020; 21(12):729-749. DOI: 10.1038/s41580-020-00294-x. View

Lin M, Chuang Y, Wu H, Hsu C, Lin N, Huang M . Targeting tumor O-glycosylation modulates cancer-immune-cell crosstalk and enhances anti-PD-1 immunotherapy in head and neck cancer. Mol Oncol. 2023; 18(2):350-368. PMC: 10850803. DOI: 10.1002/1878-0261.13489. View

Macauley M, Crocker P, Paulson J . Siglec-mediated regulation of immune cell function in disease. Nat Rev Immunol. 2014; 14(10):653-66. PMC: 4191907. DOI: 10.1038/nri3737. View

Taniguchi N, Kizuka Y . Glycans and cancer: role of N-glycans in cancer biomarker, progression and metastasis, and therapeutics. Adv Cancer Res. 2015; 126:11-51. DOI: 10.1016/bs.acr.2014.11.001. View

10.

Abastado J . The next challenge in cancer immunotherapy: controlling T-cell traffic to the tumor. Cancer Res. 2012; 72(9):2159-61. DOI: 10.1158/0008-5472.CAN-11-3538. View

11.

Xu Z, Li X, Zhou S, Xie W, Wang J, Cheng L . Systematic identification of the protein substrates of UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase-T1/T2/T3 using a human proteome microarray. Proteomics. 2017; 17(11). DOI: 10.1002/pmic.201600485. View

12.

Kim M, Yu K, Kenderian S, Ruella M, Chen S, Shin T . Genetic Inactivation of CD33 in Hematopoietic Stem Cells to Enable CAR T Cell Immunotherapy for Acute Myeloid Leukemia. Cell. 2018; 173(6):1439-1453.e19. PMC: 6003425. DOI: 10.1016/j.cell.2018.05.013. View

13.

Liu J, Wang G, Liu L, Wu R, Wu Y, Fang C . Study of the interactions of a novel monoclonal antibody, mAb059c, with the hPD-1 receptor. Sci Rep. 2019; 9(1):17830. PMC: 6882818. DOI: 10.1038/s41598-019-54231-w. View

14.

Haltiwanger R, Holt G, Hart G . Enzymatic addition of O-GlcNAc to nuclear and cytoplasmic proteins. Identification of a uridine diphospho-N-acetylglucosamine:peptide beta-N-acetylglucosaminyltransferase. J Biol Chem. 1990; 265(5):2563-8. View

15.

Carrascal M, Severino P, Cabral M, Silva M, Ferreira J, Calais F . Sialyl Tn-expressing bladder cancer cells induce a tolerogenic phenotype in innate and adaptive immune cells. Mol Oncol. 2014; 8(3):753-65. PMC: 5528624. DOI: 10.1016/j.molonc.2014.02.008. View

16.

Wandall H, Nielsen M, King-Smith S, de Haan N, Bagdonaite I . Global functions of O-glycosylation: promises and challenges in O-glycobiology. FEBS J. 2021; 288(24):7183-7212. DOI: 10.1111/febs.16148. View

17.

Sasawatari S, Okamoto Y, Kumanogoh A, Toyofuku T . Blockade of -Glycosylation Promotes Antitumor Immune Response of T Cells. J Immunol. 2020; 204(5):1373-1385. DOI: 10.4049/jimmunol.1900937. View

18.

Eichler J . Protein glycosylation. Curr Biol. 2019; 29(7):R229-R231. DOI: 10.1016/j.cub.2019.01.003. View

19.

Chen X, Sandrine I, Yang M, Tu J, Yuan X . MUC1 and MUC16: critical for immune modulation in cancer therapeutics. Front Immunol. 2024; 15:1356913. PMC: 10867145. DOI: 10.3389/fimmu.2024.1356913. View

20.

Krug J, Rodrian G, Petter K, Yang H, Khoziainova S, Guo W . N-glycosylation Regulates Intrinsic IFN-γ Resistance in Colorectal Cancer: Implications for Immunotherapy. Gastroenterology. 2022; 164(3):392-406.e5. PMC: 10009756. DOI: 10.1053/j.gastro.2022.11.018. View